Cross-Protection against Acute Staphylococcus aureus Lung Infection in Mice by a D-Glutamate Auxotrophic Vaccine Candidate.
Patricia GarcíaMaria P CabralAlejandro BeceiroMiriam MoscosoGermán BouPublished in: Vaccines (2023)
Staphylococcus aureus is regarded as a threatening bacterial pathogen causing invasive pneumonia in healthcare settings and in the community. The continuous emergence of multidrug resistant strains is narrowing the treatment options for these infections. The development of an effective S. aureus vaccine is, therefore, a global priority. We have previously developed a vaccine candidate, 132 Δ murI Δ dat , which is auxotrophic for D-glutamate, and protects against sepsis caused by S. aureus . In the present study, we explored the potential of this vaccine candidate to prevent staphylococcal pneumonia, by using an acute lung infection model in BALB/c mice. Intranasal inoculation of the vaccine strain yielded transitory colonization of the lung tissue, stimulated production of relevant serum IgG and secretory IgA antibodies in the lung and distal vaginal mucosa and conferred cross-protection to acute pneumonia caused by clinically important S. aureus strains. Although these findings are promising, additional research is needed to minimize dose-dependent toxicity for safer intranasal immunization with this vaccine candidate.
Keyphrases
- staphylococcus aureus
- respiratory failure
- healthcare
- liver failure
- multidrug resistant
- escherichia coli
- type diabetes
- drug induced
- acute kidney injury
- intensive care unit
- mechanical ventilation
- minimally invasive
- drug resistant
- adipose tissue
- skeletal muscle
- insulin resistance
- cystic fibrosis
- social media
- klebsiella pneumoniae
- community acquired pneumonia
- acute respiratory distress syndrome
- health insurance